Company intelligence / Profile preview

Plurielles

Haifa, Haifa District, Israelimagesplurielles.com ↗

Ownership: Private
Employees: ~180
Development stage: Other

Overview

Pluri has developed two main product candidates—PLX-PAD and PLX-R18—both derived from placental cells. Clinical studies have included indications such as muscle injury recovery post-surgery and ARDS due to COVID‑19. The company also explores applications in hematologic conditions and is expanding into immunotherapy for solid tumors through academic collaborations. Some programs have completed late-stage trials while others remain in early phases.

Therapeutic areas: OtherPulmonologyCardiovascularHematology
Modalities: Cell therapyAllogeneic cell therapyMesenchymal stromal cell therapy
Industry: Biotech

Partnerships

Bar-Ilan University – collaboration for cancer immunotherapy using allogeneic MAIT cellsOther partnerships not detailed in current sources.

Beyond the preview

Go deeper on Plurielles.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Plurielles.

Explore the full profile